AbbVie Inc. (ABBV)

NYSE: ABBV · USD

$246

+2.39 (+1.0%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-06 02:00 UTC. Latest published research analyzed 2026-05-08 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh ABBV analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-08

Our latest published analysis: ABBV rated Hold

Hold. Current price of $202.71 fully reflects the transition to the next-generation pipeline.

Fair value (mid)

$204 / share

$153 – $255

Upside to FV

+0.5%

from $246

Confidence

88/100

Moat

9/10

Read full analysis →

Market cap	$358.5B
Revenue (ttm)	64.4B
Net income (ttm)	6.3B
EPS (ttm)	$3.54
Shares out	1.8B
P/E (trailing)	69.6x
P/E (forward)	12.5x
Dividend	$6.92 (2.81%)
Volume	5,191,480
Beta	0.28
Price target	$273	+11.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 64.4B
Net income (ttm): 6.3B
EPS (ttm): $3.54
P/E (trailing): 69.6x
P/E (forward): 12.5x
Market cap: $358.5B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$58.05B	$54.32B	$56.33B	$61.16B	+1.8%
Gross profit	$40.64B	$33.90B	$39.43B	$42.96B	+1.9%
Operating income	$18.81B	$13.54B	$11.89B	$20.09B	+2.2%
Net income	$11.84B	$4.86B	$4.28B	$4.23B	-29.1%
EPS (diluted)	$6.63	$2.72	$2.39	$2.36	-29.1%
EBITDA	$24.17B	$17.17B	$14.91B	$17.63B	-10.0%
R&D	$6.51B	$7.68B	$12.79B	$9.10B	+11.8%
SG&A	$15.26B	$12.87B	$14.75B	$14.01B	-2.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABT	Abbott Laboratories	182.9B	34.2x	3.9x	7.5%	+3.0%	-16.8%	Strong Buy
ACN	Accenture plc	104.5B	13.7x	1.4x	27.1%	+8.8%	-31.8%	Buy
ADI	Analog Devices Inc.	184B	56.2x	14.4x	9.1%	+15.5%	+72.1%	Sell
AMGN	Amgen Inc.	220.5B	25.3x	5.8x	20.2%	+8.4%	+39.1%	Strong Buy
BIIB	Biogen Inc.	30.5B	36.6x	3.0x	8.9%	-3.0%	+56.3%	Strong Buy
BMY	Bristol-Myers Squibb Company	130B	14.0x	2.6x	21.7%	+2.1%	+46.9%	Strong Buy

All ABBV indicators

Market & fundamental data

Available fields

280

Groups with data

Currency

USD

Showing 280 of 280 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001551152
Company name	AbbVie Inc.
Country	United States
Country code	US
Cusip	00287Y109
Employees	57,000
Employees Change	2,000%
Employees Change Percent	3.64
Enterprise value	$499.4B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Drug Manufacturers - General
Industry PE	31.7
Industry PE Fwd	17.59
Isin	US00287Y1091
Last refreshed	2026-08-06
Market cap	$435.1B
Market cap category	Mega-Cap
Price	$246
Price currency	USD
Rev Per Employee	1,129,578.95x
Sector	Healthcare
Sector PE	48.47
Sector PE Fwd	22.6
Sic	2834
Symbol	ABBV
Website	https://www.abbvie.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.44%
EV Earnings	79.65x
EV Sales Forward	7.19x
EV/EBIT	29.6x
EV/EBITDA	20.19x
EV/FCF	27.42x
EV/Sales	7.76x
FCF yield	4.19%
Forward P/E	16.11x
P/E ratio	69.55x
P/S ratio	6.76x
PE Ratio10 Y	41.3x
PE Ratio3 Y	81.44x
PE Ratio5 Y	58.76x
PEG ratio	1.11x
PS Forward	6.27x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	26.2%
EBITDA Margin	38.42%
FCF margin	28.28%
Gross margin	72.79%
Gross Profit	$46.9B
Gross Profit Growth	12.78%
Gross Profit Growth Q	14.64%
Gross Profit Growth3 Y	5.88%
Gross Profit Growth5 Y	5.07%
Net Income	$6.3B
Net Income Growth	67.69%
Net Income Growth Q	285.18%
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Net Income Growth3 Y	-10.12%
Net Income Growth5 Y	-1.02%
Pretax Margin	13.51%
Profit Margin	9.8%
Profit Per Employee	$110,000
Profitable Quarters	$6
Profitable Years	17
ROA	10.51
Roa5y	8.68
ROCE	18.05
Roe5y	1,295.2
ROIC	17.7
Roic5y	21.99

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	18.84%
Cagr1y	28.75%
Cagr3y	22.72%
Cagr5y	20.78%
Div CAGR10	11.89%
Div CAGR3	5.3%
Div CAGR5	6.1%
EPS Growth	68.54
EPS Growth Q	290.4
EPS Growth Quarters	1
EPS Growth Years	0
EPS Growth3 Y	-10.05
EPS Growth5 Y	-0.92
FCF Growth	-0.16%
FCF Growth Q	-36.24%
FCF Growth3 Y	-9.78%
FCF Growth5 Y	-1.43%
OCF Growth	1.16%
OCF Growth Q	-33.32%
OCF Growth10 Y	9.1%
OCF Growth3 Y	-8.59%
OCF Growth5 Y	-0.94%
Revenue Growth	10.39x
Revenue Growth Q	10.16x
Revenue Growth Quarters	10x
Revenue Growth Years	2x
Revenue Growth3 Y	4.75x
Revenue Growth5 Y	3.69x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.47
Assets	$135.1B
Cash	$6.6B
Current Assets	$33.7B
Current Liabilities	$41.6B
Debt	$70.9B
Debt EBITDA	$2.87
Debt FCF	$3.89
Equity	$-5.9B
Interest Coverage	5.79
Liabilities	$141B
Long Term Assets	$101.4B
Long Term Liabilities	$99.4B
Net Cash	$-64.3B
Net Cash By Market Cap	$-14.78
Net Debt EBITDA	$2.6
Net Debt FCF	$3.53
Tangible Book Value	$-90.6B
Tangible Book Value Per Share	$-51.27
WACC	5.4

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.81
Inventory Turnover	3.47
Net Working Capital	$-6.2B
Quick ratio	0.49
Working Capital	$-8B
Working Capital Turnover	$-6.97

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.03%
Dividend Growth	5.56%
Dividend Growth Years	54%
Dividend per share	$6.92
Dividend Years	54
Dividend Yield	2.81%
Ex Div Date	2026-07-15
Last Dividend	$1.73
Payout Frequency	Quarterly
Payout Ratio	195.5%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	461.49%
1Y total return	28.73%
200-day SMA	225
3Y total return	84.85%
50-day SMA	239.9
50-day SMA vs 200-day SMA	50over200
5Y total return	157.03%
All Time High	267.5
All Time High Change	-7.95%
All Time High Date	2026-07-29
All Time Low	32.51
All Time Low Change	657.31%
All Time Low Date	2012-12-17
ATR	6.74
Beta	0.28
Beta1y	-0.46
Beta2y	0.13
Ch YTD	7.75
High	249.4
High52	267.5
High52 Date	2026-07-29
High52ch	-7.95%
Low	243.8
Low52	190.8
Low52 Date	2026-04-29
Low52ch	29.07%
Ma50ch	2.61%
Premarket Change Percent	0.64
Premarket Price	$245
Premarket Volume	1,397
Price vs 200-day SMA	9.44%
RSI	46.91
RSI Monthly	64.17
RSI Weekly	59.92
Sharpe ratio	0.95x
Sortino ratio	1.72
Total Return	2.78%
Tr YTD	10.3
Tr1m	-5.02%
Tr1w	-6.49%
Tr3m	19.12%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	31
Analyst Count Top	18
Analyst Price Target Top	$275
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$3.77
Earnings EPS Estimate Growth	26.94
Earnings Revenue Estimate	16,760,124,088x
Earnings Revenue Estimate Growth	8.67x
Operating Income	$22.9B
Operating Income Growth	21.17
Operating Income Growth Q	17.54
Operating Income Growth3 Y	3.56
Operating Income Growth5 Y	3.75
Operating margin	35.56
Price target	$273
Price Target Change	$11.04
Price Target Change Top	$11.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,763,944,143%
Float Percent	99.82%
Net Borrowing	418,000,000
Shares Insiders	0.07%
Shares Institutions	75.88%
Shares Out	1,767,117,285
Shares Qo Q	-0.23%
Shares Yo Y	0.03%
Short Float	1.28%
Short Ratio	2.42
Short Shares	1.28

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$17.2B
Adjusted OCF	18,531,000,000
Average Volume	5,564,490.8x
Bv Per Share	-3.36
CAPEX	$-1.3B
Ch10y	272.5
Ch1m	-5.7
Ch1w	-6.49
Ch1y	24.85
Ch3m	18.27
Ch3y	66.66
Ch5y	113.9
Ch6m	13.4
Change	0.98%
Change From Open	-0.32
Close	243.8
Days Gap	1.31
Depreciation Amortization	7,869,000,000
Dollar Volume	1,278,142,376
Earnings Date	2026-07-31
Earnings Time	bmo
EBIT	$16.9B
EBITDA	$24.7B
EPS	$3.54
F Score	8
FCF	$18.2B
FCF EV Yield	3.65x
FCF Per Share	$10.3
Financing CF	-12,891,000,000
Fiscal Year End	December
Founded	2,012
Goodwill	35,519,000,000
Income Tax	$2.4B
Investing CF	-6,498,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-31
Last Report Date	2026-06-30
Last Split Type	Never
Last10k Filing Date	2026-02-20
Lynch Fair Value	$17.7
Lynch Upside	-92.81
Ma150	224.4
Ma150ch	9.74%
Ma20	252.5
Ma20ch	-2.49%
Net CF	102,000,000
Next Earnings Date	2026-10-30
Open	247
Optionable	Yes
P FCF Ratio	23.89
P FCF Ratio SBC	25.24
P OCF Ratio	22.3
P OCF Ratio SBC	23.48
Payment Date	2026-08-14
Position In Range	43.42
Post Close	246.2
Postmarket Change Percent	0.12
Postmarket Price	$247
Ppne	5,796,000,000
Pre Close	243.8
Price Date	2026-08-05
Price EBITDA	$17.59
Relative Volume	0.93x
Revenue	64,386,000,000x
SBC By Revenue	1.52x
Share Based Comp	976,000,000
Tax By Revenue	3.7x
Tax Rate	27.39%
Tr6m	15.15%
Us State	Illinois
Views	578
Volume	5,191,480
Z Score	2.42

Frequently asked questions

About this ABBV report

What is the latest published ABBV stock rating?

AbbVie Inc. is shown with hold in the latest published report, analyzed 2026-05-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ABBV analysis?

The full latest published report, analyzed 2026-05-08, lives at /stocks/ABBV/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for ABBV?

The latest published report analyzed 2026-05-08 frames ABBV around USD 153 to USD 255. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the ABBV page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

AbbVie Inc. (ABBV)

Coverage state: Latest published research available

Generate a fresh ABBV analysis

Our latest published analysis: ABBV rated Hold

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ABBV

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All ABBV indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ABBV

Frequently asked questions